Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532447 | 1.00 | CCR1 (0.42) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL14659501 | 0.88 | CCR1 (0.40) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL14659500 | 0.88 | CCR1 (0.40) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL2598564 | 0.86 | GAA (0.47) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL2598566 | 0.86 | GAA (0.47) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL3689050 | 0.86 | GAA (0.47) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL1774177 | 0.85 | GAA (0.44) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL1774175 | 0.85 | GAA (0.44) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL1774040 | 0.84 | GAA (0.49) | CCR1GAAKDM4EPOLBTSHR | |
| SCHEMBL3681642 | 0.83 | GAA (0.48) | CCR1GAAKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376487-B1 | THIAZOLYL OXIME ETHER AND HYDRAZONES AS PLANT PROTECTION AGENT | BAYER IP GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-9215875-B2 | Thiazolyl oxime ethers and hydrazones as crop protection agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-22 | — | — | US | disclosed |
| US-20140296289-A1 | Thiazolyl Oxime Ethers and Hydrazones as Crop Protection Agents | BAYER CROPSCIENCE AG (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8697878-B2 | Thiazolyl oxime ethers and hydrazones as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2014-04-15 | — | — | US | disclosed |
| CN-102292334-A | Thiazolyl oxime ether and hydrazones asl plant protection agent | — | 2011-12-21 | — | — | CN | disclosed |
| EP-2376487-A1 | THIAZOLYL OXIME ETHER AND HYDRAZONES ASL PLANT PROTECTION AGENT | Bayer CropScience AG (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20100190828-A1 | Thiazolyl oxime ethers and hydrazones as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2010-07-29 | — | — | US | disclosed |
| WO-2010066353-A1 | THIAZOLYL OXIME ETHER AND HYDRAZONES ASL PLANT PROTECTION AGENT | BAYER CROPSCIENCE AG (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296289-A1 | Thiazolyl Oxime Ethers and Hydrazones as Crop Protection Agents | OXSR1, FOXO1, HAX1 | CCR1 3055/4885GAA 1697/4885KDM4E 915/4885 |
| US-20100190828-A1 | Thiazolyl oxime ethers and hydrazones as crop protection agents | OXSR1, FOXO1, HAX1 | CCR1 3055/4885GAA 1697/4885KDM4E 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.